Treatment with ivermectin has proven effective for fighting onchocerciasis; contributing to transmission interruption or elimination in many countries. The Centre for Research on Filariasis and Other Tropical Diseases explored the feasibility of partially integrating ivermectin administration into Cameroon’s primary health care system. Specifically, researchers examined ivermectin campaign costs and the opportunities and obstacles associated with partially integrating ivermectin campaigns. They held interviews and focus groups with stakeholders and analyzed data from previous ivermectin campaigns in five regions of Cameroon.
While many countries impacted by onchocerciasis have eliminated the disease, it remains endemic in 60% of Cameroon’s health districts. This prevalence points to a gap in the implementation of ivermectin treatment in Cameroon. Absences during mass drug administration (MDA) campaigns and the failure of community drug distributors to deliver treatments have contributed significantly to this gap in coverage. Thus, the Centre for Research on Filariasis and Other Tropical Diseases explored the potential partial integration of this intervention with Cameroon’s primary health care system as an approach to improving ivermectin coverage.
The objectives of this study were to:
This study revealed the following opportunities associated with the partial integration of ivermectin distribution in Cameroon:
Dr. Guy Sadeu Wafeu of the Center for Research on Filariasis and Other Tropical Diseases, presents the results, lessons and promising practices.
Study participants identified the following challenges in connection to partial implementation:
To help mitigate these challenges, participants recommended the following strategies:
By analyzing data from the most recent mass ivermectin administration, researchers found the following: